Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

ClinicalTrials.gov ID: NCT01624285

Public ClinicalTrials.gov record NCT01624285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)

Study identification

NCT ID: NCT01624285
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

laboratory biomarker analysis Other
placebo Other
sorafenib tosylate Drug

Other · Drug

Eligibility (public fields only)

Age range: 19 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2012
Primary completion: Jan 31, 2023
Completion: Jan 31, 2023
Last update posted: Dec 13, 2023

2012 – 2023

United States locations

U.S. sites: 21
U.S. states: 19
U.S. cities: 19

Facility	City	State	ZIP	Site status
University of Alabama	Birmingham	Alabama	35294-0007	—
Jonsson Comprehensive Cancer Center	Los Angeles	California	90095	—
University of Colorado	Denver	Colorado	80217-3364	—
Mount Sinai Hospital	Hartford	Connecticut	06112	—
Lombardi Comprehensive Cancer Center at Georgetown University	Washington D.C.	District of Columbia	20057	—
Emory University	Atlanta	Georgia	30322	—
Northwestern University	Chicago	Illinois	60611	—
Ochsner Clinic Foundation	New Orleans	Louisiana	70121	—
Johns Hopkins University	Baltimore	Maryland	21287-8936	—
Lahey Clinic Medical Center	Burlington	Massachusetts	01805	—
University of Michigan University Hospital	Ann Arbor	Michigan	48109	—
University of Nebraska Medical Center	Omaha	Nebraska	68198-7830	—
University of Pennsylvania Health System	Cherry Hill	New Jersey	08034	—
New York University Langone Medical Center	New York	New York	10016	—
New York Presbyterian-The University Hospital of Columbia and Cornell	New York	New York	10065	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Integris-Baptist Medical	Oklahoma City	Oklahoma	73112	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15213	—
Vanderbilt University	Nashville	Tennessee	37232	—
Baylor College of Medicine	Houston	Texas	77030	—
The Methodist Hospital Research Institute	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01624285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 13, 2023 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01624285 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →